Izzo Ilaria, Zanotti Paola, Chirico Claudia, Casari Salvatore, Villanacci Vincenzo, Salemme Marianna, Biasi Luciano, Festa Elena, Castelli Francesco
University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy.
Spedali Civili General Hospital, Pathology Institute, Brescia, Italy.
Infection. 2016 Dec;44(6):811-812. doi: 10.1007/s15010-016-0915-x. Epub 2016 Jun 16.
Since 2014 several direct-acting antivirals (DAAs) have been made available, allowing interferon-free antiviral treatments with high sustained virological response rates. Side effects are, however, a real challenge during treatment. Sarkar et al. recently published a case of colitis following initiation of sofosbuvir and simeprevir for genotype 1 hepatitis C. We report the case of a patient with no prior history of inflammatory bowel disease, who developed significant bloody diarrhea within 3 weeks of sofosbuvir/simeprevir/ribavirin initiation. Colonoscopy and biopsy suggested a drug-induced colitis.
自2014年以来，已有多种直接抗病毒药物（DAA）可供使用，从而实现了无干扰素的抗病毒治疗，且持续病毒学应答率很高。然而，治疗期间的副作用是一个切实存在的挑战。萨卡尔等人最近发表了一例在开始使用索磷布韦和西米普明治疗1型丙型肝炎后发生结肠炎的病例。我们报告了一例既往无炎症性肠病病史的患者，该患者在开始使用索磷布韦/西米普明/利巴韦林治疗的3周内出现了严重的血性腹泻。结肠镜检查和活检提示为药物性结肠炎。
